-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Speaking of the virus, the first reaction of many people is probably to hate it and stay away from it
.
However, there is a special type of virus-oncolytic virus-that can help humans deal with tumors, and even the most difficult king of cancers-pancreatic cancer
.
New research shows that the oncolytic virus H-1PV shows considerable safety and signs of immune system activation in patients with metastatic pancreatic ductal adenocarcinoma (PDAC)
.
Pancreatic ductal adenocarcinoma (PDAC) is difficult to treat.
Pancreatic ductal adenocarcinoma is a malignant tumor with a very poor clinical prognosis.
It is usually diagnosed at an advanced stage and cannot be cured.
The median overall survival is less than one year
.
In the past decades of medical research, the improvement in the efficacy of pancreatic ductal adenocarcinoma has been minimal—the typical representative of immunotherapy, immune checkpoint inhibitors, is ineffective, and targeted therapy is only feasible in rare cases
.
For the vast majority of patients, the current treatment options are still very limited
.
Therefore, the need for innovative treatments for anti-pancreatic ductal adenocarcinoma is imminent
.
Can oncolytic virus therapy be able to clear the cloud? Oncolytic virus is a unique anti-cancer virus.
This virus can preferentially infect and lyse cancer cells.
It can also induce an anti-tumor immune response: the human body will produce when an unknown virus invades.
After a series of immune responses, the immune effector cells of the whole body will become active against the virus.
At the same time, the cancer cells present in the body will also be attacked by the immune system, which can be described as killing two birds with one stone
.
In addition, certain characteristics of cancer cells can attract viruses, so the immune response at the tumor site may be particularly strong
.
These factors work together to finally achieve the goal of disease control
.
Oncolytic virus therapy has become an emerging treatment method in the field of tumor immunology
.
The rodent protozoal virus H-1 (H-1PV) is an oncolytic virus that has proven anti-cancer effects in tumors and animal models
.
In a phase 2 clinical study involving 7 patients with pancreatic ductal adenocarcinoma, H-1PV showed good tolerability, safety and feasibility; among them, 2 patients achieved a longer survival period (326 days and 555 days).
Day), showing signs of immune system activation, which confirmed that H-1PV is beneficial to anti-cancer immune regulation
.
Figure 1.
The trial administration process combined with intravenous and lesion administration.
Seven patients with metastatic pancreatic ductal adenocarcinoma received three different doses of H-1PV, and 10% of the total dose was injected intravenously every day for 4 consecutive days
.
After 6-13 days, the remaining 60% of H-1PV will be injected directly into the liver metastases of the cancer
.
Gemcitabine was used for drug treatment on the 28th day
.
With a combination of systemic and local administration, the reactions of various tissues in the body can be observed separately
.
Intravenous injection can explore the tendency and aggregation site of the virus, and local administration avoids the virus from being neutralized in the systemic circulation, thereby maximizing the local curative effect
.
The treatment is ingenious and kills two birds with one stone
.
There were no serious side effects during safe and non-toxic medication.
Mild and moderate increase in serum C-reactive protein were the only adverse reactions related to H1-PV
.
Virus transmission analysis further verified its safety: no matter what dose of H1-PV, after intravenous injection, the infectious virus disappears in the blood in the form of neutralizing antibodies within 3 to 8 days; it is injected into the liver and transferred After the focus, 5 of the 7 patients detected a small amount of virus in the stool, and there were no active virus particles in the saliva and urine samples
.
The true and effective median progression-free survival of immune activation was 72 days, and the median overall survival was 175 days
.
Through the nucleic acid detection of H-1PV, all subjects showed T cell responses to viral proteins
.
Among them, two patients No.
4 and No.
6 had partial remission, and their progression-free survival periods were 177 days and 176 days, respectively
.
Both patients agreed to continue the survival follow-up after the trial ended
.
They survived for 326 days and 555 days, respectively, which is not easy for metastatic pancreatic cancer with a very poor prognosis
.
Both patients had specific anti-tumor immune characteristics
.
The T cell infiltration sampled from the tumor tissue of patient No.
4 is shown in Figure 2.
The T cell infiltration was significantly increased after 2 months of intratumoral administration of H-1PV.
The arrow below B marks the area with particularly dense cells
.
At the same time, an increase in the number of activated T cells in the blood of the two patients and changes in pro-inflammatory cytokines in the tumor microenvironment were also observed
.
Figure 2.
4 Increased T cell infiltration in the tumor of patient No.
2.
4 Although the number of patients in this study is limited and the correlation of the data cannot be confirmed, the activation and regulation effect of H-1PV on the immune system cannot be ignored
.
As the first clinical trial of an oncolytic virus in the treatment of pancreatic ductal adenocarcinoma, the feasibility of this treatment path has been verified, and it has laid the foundation for the further use of oncolytic virus alone or in combination with other therapies for systemic clinical development
.
I believe that in the near future, pancreatic ductal adenocarcinoma can be overcome by advances in medicine
.
Pay attention to more cutting-edge anti-cancer information with Cancer Degree
.
Welcome to download the Cancer Degree APP .
Reference: Hajda J.
, et al.
"Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Immune Cell Activity in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
" Clinical Cancer Research, 2021, p.
clincanres.
1020.
2021.
Crossref, doi:10.
1158/1078-0432.
ccr-21-1020.
Click below to learn more about the clinical trial items Cancer Degree/Color/Recommendation/Recommend 0102 Slide to see more
.
However, there is a special type of virus-oncolytic virus-that can help humans deal with tumors, and even the most difficult king of cancers-pancreatic cancer
.
New research shows that the oncolytic virus H-1PV shows considerable safety and signs of immune system activation in patients with metastatic pancreatic ductal adenocarcinoma (PDAC)
.
Pancreatic ductal adenocarcinoma (PDAC) is difficult to treat.
Pancreatic ductal adenocarcinoma is a malignant tumor with a very poor clinical prognosis.
It is usually diagnosed at an advanced stage and cannot be cured.
The median overall survival is less than one year
.
In the past decades of medical research, the improvement in the efficacy of pancreatic ductal adenocarcinoma has been minimal—the typical representative of immunotherapy, immune checkpoint inhibitors, is ineffective, and targeted therapy is only feasible in rare cases
.
For the vast majority of patients, the current treatment options are still very limited
.
Therefore, the need for innovative treatments for anti-pancreatic ductal adenocarcinoma is imminent
.
Can oncolytic virus therapy be able to clear the cloud? Oncolytic virus is a unique anti-cancer virus.
This virus can preferentially infect and lyse cancer cells.
It can also induce an anti-tumor immune response: the human body will produce when an unknown virus invades.
After a series of immune responses, the immune effector cells of the whole body will become active against the virus.
At the same time, the cancer cells present in the body will also be attacked by the immune system, which can be described as killing two birds with one stone
.
In addition, certain characteristics of cancer cells can attract viruses, so the immune response at the tumor site may be particularly strong
.
These factors work together to finally achieve the goal of disease control
.
Oncolytic virus therapy has become an emerging treatment method in the field of tumor immunology
.
The rodent protozoal virus H-1 (H-1PV) is an oncolytic virus that has proven anti-cancer effects in tumors and animal models
.
In a phase 2 clinical study involving 7 patients with pancreatic ductal adenocarcinoma, H-1PV showed good tolerability, safety and feasibility; among them, 2 patients achieved a longer survival period (326 days and 555 days).
Day), showing signs of immune system activation, which confirmed that H-1PV is beneficial to anti-cancer immune regulation
.
Figure 1.
The trial administration process combined with intravenous and lesion administration.
Seven patients with metastatic pancreatic ductal adenocarcinoma received three different doses of H-1PV, and 10% of the total dose was injected intravenously every day for 4 consecutive days
.
After 6-13 days, the remaining 60% of H-1PV will be injected directly into the liver metastases of the cancer
.
Gemcitabine was used for drug treatment on the 28th day
.
With a combination of systemic and local administration, the reactions of various tissues in the body can be observed separately
.
Intravenous injection can explore the tendency and aggregation site of the virus, and local administration avoids the virus from being neutralized in the systemic circulation, thereby maximizing the local curative effect
.
The treatment is ingenious and kills two birds with one stone
.
There were no serious side effects during safe and non-toxic medication.
Mild and moderate increase in serum C-reactive protein were the only adverse reactions related to H1-PV
.
Virus transmission analysis further verified its safety: no matter what dose of H1-PV, after intravenous injection, the infectious virus disappears in the blood in the form of neutralizing antibodies within 3 to 8 days; it is injected into the liver and transferred After the focus, 5 of the 7 patients detected a small amount of virus in the stool, and there were no active virus particles in the saliva and urine samples
.
The true and effective median progression-free survival of immune activation was 72 days, and the median overall survival was 175 days
.
Through the nucleic acid detection of H-1PV, all subjects showed T cell responses to viral proteins
.
Among them, two patients No.
4 and No.
6 had partial remission, and their progression-free survival periods were 177 days and 176 days, respectively
.
Both patients agreed to continue the survival follow-up after the trial ended
.
They survived for 326 days and 555 days, respectively, which is not easy for metastatic pancreatic cancer with a very poor prognosis
.
Both patients had specific anti-tumor immune characteristics
.
The T cell infiltration sampled from the tumor tissue of patient No.
4 is shown in Figure 2.
The T cell infiltration was significantly increased after 2 months of intratumoral administration of H-1PV.
The arrow below B marks the area with particularly dense cells
.
At the same time, an increase in the number of activated T cells in the blood of the two patients and changes in pro-inflammatory cytokines in the tumor microenvironment were also observed
.
Figure 2.
4 Increased T cell infiltration in the tumor of patient No.
2.
4 Although the number of patients in this study is limited and the correlation of the data cannot be confirmed, the activation and regulation effect of H-1PV on the immune system cannot be ignored
.
As the first clinical trial of an oncolytic virus in the treatment of pancreatic ductal adenocarcinoma, the feasibility of this treatment path has been verified, and it has laid the foundation for the further use of oncolytic virus alone or in combination with other therapies for systemic clinical development
.
I believe that in the near future, pancreatic ductal adenocarcinoma can be overcome by advances in medicine
.
Pay attention to more cutting-edge anti-cancer information with Cancer Degree
.
Welcome to download the Cancer Degree APP .
Reference: Hajda J.
, et al.
"Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Immune Cell Activity in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
" Clinical Cancer Research, 2021, p.
clincanres.
1020.
2021.
Crossref, doi:10.
1158/1078-0432.
ccr-21-1020.
Click below to learn more about the clinical trial items Cancer Degree/Color/Recommendation/Recommend 0102 Slide to see more
